{"ticker": {"uuid": "807623af-912b-4e31-ba16-27fddce53744", "symbol": "KMDA", "name": "Kamada", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Kamada highlights study results on CYTOGAM in transplants", "summary": "Kamada Ltd. presented positive study results for its CYTOGAM product at a recent International Society for Heart and Lung Transplant meeting, showing improved outcomes for high-risk lung transplant recipients. The company, which reported strong Q1 2026 revenues and reaffirmed its", "url": "https://www.investing.com/news/company-news/kamada-highlights-study-results-on-cytogam-in-transplants-93CH-4788076", "source_name": "Investing.com", "published_at": "2026-07-14T07:10:15", "published_display": "14 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNnY3NUlJT09nNzZtekkzTXdjYkhrVWhMbjBtZGVWOUxDRmh0RmRrX0hpdVljUDBneVZ6aWtfV3pGNUtia0NhSzhpeWotYTRmeGh0cFBvMzJzaEdnNnBmS21fM1ZrODlzSHllVjBiSkFkZUh2SnJtTkZITVVjVXhWamhrVTB1NmhDY2JpSlFCb0k0ZEVGbGJydEY1TWtGd1g2V0I5OG1rb3JVYl9YYnpuSzB3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T12:17:22+00:00", "published_display": "13 Jul 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada highlights study results on CYTOGAM in transplants By Investing.com", "summary": "Kamada Ltd. announced positive results from an investigator-initiated study on its CYTOGAM product for solid organ transplantation, presented at the 2026 International Society for Heart and Lung Transplant annual meeting. The study indicated that high-risk lung transplant recipie", "url": "https://ng.investing.com/news/stock-market-news/kamada-highlights-study-results-on-cytogam-in-transplants-93CH-2596484", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:40:59", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC Filing - Form 6-K", "summary": "Kamada Ltd. (NASDAQ: KMDA) has filed a Form 6-K report highlighting new results from an Investigator-Initiated Study on its Cytomegalovirus Immune Globulin (CMVIG), CYTOGAM\u00ae, presented at the 2026 ISHLT annual meeting. The study indicates that CMVIG prophylaxis is associated with", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-ee81347ac99e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:12:08", "published_display": "13 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Highlights CYTOGAM\u00ae Study Results Presented at the 2026 ISHLT Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kamada-highlights-cytogam-study-results-110000518.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immune drug CYTOGAM tied to better outcomes in high\u2011risk lung transplant patients", "summary": "Kamada (NASDAQ: KMDA) announced new data from an Investigator-Initiated Study demonstrating that its immune globulin product, CYTOGAM, is associated with improved outcomes in high-risk lung transplant recipients. Presented at the 2026 ISHLT annual meeting, the findings, which com", "url": "https://www.stocktitan.net/news/KMDA/kamada-highlights-cytogam-study-results-presented-at-the-2026-ishlt-re84r7b7tu3n.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:12:08", "published_display": "13 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (KMDA) Movements Inform Risk Allocation Models", "summary": "This article analyzes Kamada Ltd. (NASDAQ: KMDA) using AI models, identifying weak near-term sentiment but strong long-term potential. It provides three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The anal", "url": "https://news.stocktradersdaily.com/news_release/134/How_KMDA_Movements_Inform_Risk_Allocation_Models_071226044602_1783845962.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T06:45:52", "published_display": "12 Jul 2026 06:45", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kamada Ltd. \u2013 NASDAQ:KMDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPUUFXYjNmTjJFeDlMSm1wbnoxRzVyakk5TnlEem40RGVNUzFQR2RRUGYyMGN1VFM0eUJSTGs3V09hV3Bla0htWGJta3ZfamZIYVJOcll1dURBUWNCRW05S3NJLXA4Zjd0eGd6R0FmaFRNSndDdkVSX01sWU9UcEdWMlpvZnRUMVJWMmNmVmpiNGxhMjg3YkFMbHRuRVBkUDgyNEE?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T12:27:56+00:00", "published_display": "10 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd outlines plasma-derived therapies strategy. Investor focus on specialty biologics pipeline grows", "summary": "Kamada Ltd (KMDA) is a specialty biopharmaceutical company focused on plasma-derived and other biologic therapies for rare and serious conditions, listed on Nasdaq. The company's strategy involves controlling plasma fractionation, focusing on rare disease markets with in-house de", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-outlines-plasma-derived-therapies-strategy-investor-focus-on/69717196", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:30:00", "published_display": "07 Jul 2026 21:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines Slightly - Post-Earnings Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOeWM5S3ZIRnlycE1yVW5STnV0azdHVmdOWHREWFM5XzNxWDdaVTlLWWpuRGpGOHZCNU9tOV91UElBU3lLb1JyYU5TaVg5dVVPUUFxLXF1eTRtTzJFbG9MR1ZwTGJuRTY5ZGVQdTBubUxGcEdESUpIRFlwN2dYUWQ2NWJEWU9qU1V0dHBDVXdfbk1paEJMeFJjYkNaOXNJVDdTdWxnMmhSTV9sRUxjQXdUN1BpWjFxcGFs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-05T12:43:48+00:00", "published_display": "05 Jul 2026 12:43", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines Slightly - Trough Earnings Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPa256VkpYU3Q3Q1FCejJxMGFObWhpenlpLVpmaWh4VEx2TnVoZHhUWm5NSHYxdGVnblpZZTFPcWM2SHVhZWYxZkFxQ3NoeUVqQzl4a3A0SGc1UEhPZGQySkwydS1SWHlwbFlIS0xwZXBTNVY3TUJKVXByX1Z2SnNqUDdjaDVSd0tRSWg4TGpPNzAycF9VUWtmTlpaTVRHUzVGOXFFam5rUnFaTEhia0xjYWxDLVpLMXhSd0hrRA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd updates drug portfolio as Nasdaq-listed biopharma pursues growth", "summary": "Kamada Ltd, a Nasdaq-listed biopharma company, is refining its drug portfolio, focusing on specialty plasma-derived and hyperimmune globulin products for rare and underserved indications. The company, headquartered in Israel, offers US investors exposure to its niche through Amer", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-updates-drug-portfolio-as-nasdaq-listed-biopharma-pursues/69661013", "source_name": "AD HOC NEWS", "published_at": "2026-06-30T12:40:37", "published_display": "30 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Corporate Presentation Summary", "summary": "This article summarizes a corporate presentation by Kamada (KMDA) from December 12, 2025, highlighting its strong financial performance with 2025 revenue guidance of $178\u2013182M and significant year-over-year growth in revenue, gross profit, and adjusted EBITDA. The company boasts ", "url": "https://quartr.com/events/kamada-kmda-corporate-presentation_F9yDDt1k", "source_name": "Quartr", "published_at": "2026-06-27T17:39:51", "published_display": "27 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KMDA Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article analyzes Kamada Ltd's (KMDA) financial performance, highlighting its revenue breakdown, profitability margins, and competitive standing. Proprietary Products contribute the majority (85.9%) of its revenue. KMDA's margins, including a gross margin of 42.25% and a net m", "url": "https://intellectia.ai/en/stock/KMDA/financials", "source_name": "Intellectia AI", "published_at": "2026-06-23T23:41:20", "published_display": "23 Jun 2026 23:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Stock - weekly review against biotech peers", "summary": "This article provides a weekly review of Kamada stock (KMDA), noting its quiet trading in the mid-single digits without fresh company news. The focus is on how Kamada, an Israeli plasma-derived protein specialist, compares to its mid-cap biotech peers and its recent fundamentals.", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-stock-weekly-review-against-biotech-peers/69585732", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T20:18:33", "published_display": "19 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kamada Ltd (KMDA) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have an average price target of $13.00 for KMDA, with a \"Buy\" trend recommendation from three analysts. The company's expected revenue for the next quarter is $50.66M,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:11:00", "published_display": "18 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada schedules annual shareholder meeting for August in Rehovot", "summary": "Kamada Ltd. (NASDAQ:KMDA) has announced that its Annual General Meeting of Shareholders will be held on Wednesday, August 5, 2026, at 4:00 p.m. Israel time. The meeting will take place at the company's offices in Rehovot, Israel. A notice and proxy statement have been prepared an", "url": "https://www.investing.com/news/sec-filings/kamada-schedules-annual-shareholder-meeting-for-august-in-rehovot-93CH-4749556", "source_name": "Investing.com", "published_at": "2026-06-18T11:39:32", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (NASDAQ: KMDA) plans 2026 AGM on directors, option grants and ISO pool", "summary": "Kamada Ltd. will hold its Annual General Meeting of Shareholders on August 5, 2026, to vote on the re-election of directors, approve equity option grants for nominees, and amend the U.S. Taxpayers Appendix of its 2011 Israeli Share Award Plan to increase the incentive stock optio", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-ea617ad2d2c4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T10:39:32", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Kamada Ltd (KMDA), noting its current valuation score of 8.07, which ranks it 113 out of 157 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 20.72, showing a significant deviation from its recent high and low", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:32", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kamada Ltd (KMDA), detailing its current price momentum score of 6.81, ranking 96 out of 157 in the Pharmaceuticals industry. It highlights the stock trading between resistance at $7.84 and support at $6.88, suggesting suitability for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:32", "published_display": "18 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Kamada Ltd (KMDA), detailing its current risk score of 4.17 and ranking it 91 out of 157 in the Pharmaceuticals industry. Key metrics like beta (0.87), maximum drawdown, volatility, and Sharpe ratios are presented to illustrate the stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T07:11:10", "published_display": "18 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kamada Ltd (KMDA), detailing its revenue by region. The data shows the United States accounts for the majority of revenue at 55.22%, followed by Israel, Latin America, Canada, and Europe. The report also notes that specific data for b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:11:10", "published_display": "18 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after rece", "summary": "Kamada Ltd, an Israeli biopharmaceutical company, specializing in plasma-derived products and inhaled therapies, has experienced recent stock weakness despite its strategic focus. The company develops and markets treatments for rare and serious conditions, including alpha-1 antit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-stock-il0010952647-biopharma-player-focuses-on-plasma-and/69515074", "source_name": "AD HOC NEWS", "published_at": "2026-06-11T05:40:48", "published_display": "11 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after recent share weakness", "summary": "Kamada Ltd, an Israeli biopharma company, continues to focus on specialty plasma-derived products and inhaled therapies despite recent stock weakness. The company develops, manufactures, and markets products for rare and serious conditions, including AAT deficiency and immune def", "url": "https://www.ad-hoc-news.de/news/ueberblick/kamada-ltd-stock-il0010952647-biopharma-player-focuses-on-plasma-and/69515074", "source_name": "AD HOC NEWS", "published_at": "2026-06-10T15:10:40", "published_display": "10 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory", "summary": "Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, will enhance Kamada's capabilities for Anti-Rabies potency testin", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kamada-announces-fda-approval-house-110000158.html", "source_name": "Market source", "published_at": "2026-06-03T20:10:39", "published_display": "03 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada receives FDA approval for rabies antibody testing lab", "summary": "Kamada Ltd. announced that the U.S. FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel for potency testing of its anti-rabies products, KEDRAB and KAMRAB. This approval follows prior authorizations from Health Canada and the Isr", "url": "https://www.investing.com/news/company-news/kamada-receives-fda-approval-for-rabies-antibody-testing-lab-93CH-4718870", "source_name": "Investing.com", "published_at": "2026-06-02T02:39:01", "published_display": "02 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada receives FDA approval for rabies antibody testing lab By Investing.com", "summary": "Kamada Ltd. announced FDA approval for its new Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel. This lab will conduct potency testing for their anti-rabies products, KEDRAB and KAMRAB, which generated over $70 million in sales in 2025. The approval is expecte", "url": "https://ca.investing.com/news/stock-market-news/kamada-receives-fda-approval-for-rabies-antibody-testing-lab-93CH-4668431", "source_name": "Investing.com Canada", "published_at": "2026-06-01T11:40:20", "published_display": "01 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rabies antibody testing: FDA approves Kamada\u2019s rare gold-standard lab", "summary": "Kamada (NASDAQ: KMDA) has received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory located in Beit Kama, Israel. This lab significantly expands the company's testing capabilities for its anti-rabies products", "url": "https://www.stocktitan.net/news/KMDA/kamada-announces-fda-approval-of-its-new-in-house-rabies-virus-k1oab5qc525f.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:40:20", "published_display": "01 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) wins FDA approval for in-house RFFIT rabies antibody testing lab", "summary": "Kamada Ltd. (NASDAQ: KMDA) announced that the FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This lab, located in Israel and previously approved by Health Canada and the Israeli Ministry of Health, will be used for Anti-Rabies potenc", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-a7d7be1d4fdb.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:40:20", "published_display": "01 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KMDA - Kamada Ltd Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Kamada Ltd (KMDA), a biopharmaceutical company specializing in plasma-derived therapeutics. It includes real-time stock quotes, key financial metrics, insider ownership, analyst ratings, and a chronological list of r", "url": "https://finviz.com/stock?t=KMDA", "source_name": "Finviz", "published_at": "2026-06-01T02:08:54", "published_display": "01 Jun 2026 02:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Holds Steady Near Support as Trading Volume Remains Moderate - Shakeout Pattern", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPVTFveUJILVExTmdVTDNjQmd0UzRQNnV3SXM4MGd6Zk8xcGttMXRKTVdyV2Q0QnFRRGg0aVRiRXdrSGJCZGcxOG03MHFJTEUxbTVER1FmYW80R1BSQU9jSGxnYy0xOGo4TGFqSmdnWENDcDhobFFVQm03YURIN0pKaXZPeTR6V1JpY2tpd2hvbHd6a3FtOC1OdkFEaS1CNFVPYXY5UDFlN09LUk9FTTlBODZzYmo3VVU0WVVz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Edges Lower: Key Levels to Watch Amid Sector Dynamics - Bull Flag", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ2x5YzVLS1JVT2MtQzFmQ0YzLTR4OW5yNW8tUVBnbjFaal9MdjRSbHJmT0ZFQzhNSlRpdWJySm53bzhHSWVPelFFQ3JObWNBN2c0allTa3ZQRk12MHlBOWcybHZEdUp6UUFYRjk2Zlp2a0VxTndMY2JpNUdjeEFpemVwSENwZUc4MEppVFRTXzBQcmtEVjk3bHB4cmFpQUlsTXZ5QzVaTzh1dmdOMmpMa0YyR0xZSHlT?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Edges Lower: Key Levels to Watch Amid Sector Dynamics - Volume Rate Change", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMjhSWXVuckpYenZuT0FOMzdzS1VUUHRvNi1jbjZiWms2RUthWElsQVlwNFF6cXdNekFWU0dBY3ltYWV6aVVPU09wLU1iU0FYMW9PZEg1d3pfdVVXTkhHd2tiRkg4S0k0NUh0WUZRRXNoNExwRmhPOUpjZWw0SEV2aWlxZUNIQ2FLQ1JDUjM5RzZtaTZXRmRMWUJPOU4xNzhDeG5aRmJwWko2SldwVzJDWXFYSVBWQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me", "summary": "Kamada Ltd (KMDA) shares are stabilizing on Nasdaq following its latest quarterly update, which provided fresh insight into its revenue and margin trends for 2025. Investors are now reassessing the Israeli biopharmaceutical group's earnings profile and valuation multiples, contri", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-stock-il0010952647-shares-stabilize-after-recent-results-as/69439344", "source_name": "Ad Hoc News", "published_at": "2026-05-29T06:39:23", "published_display": "29 May 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Q1 Earnings Call Highlights", "summary": "Kamada reiterated its full-year 2026 outlook, with management stating that Q1 results were in line with expectations despite a temporary shipment delay. The company projects revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million for 2026, driven", "url": "https://www.tradingview.com/news/marketbeat:3f5df9636094b:0-kamada-q1-earnings-call-highlights/", "source_name": "TradingView", "published_at": "2026-05-28T00:40:04", "published_display": "28 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kamada-ltd-kmda-q1-2026-230135936.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:01:35+00:00", "published_display": "13 May 2026 23:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/3e7bb77a-ff9d-3541-9e49-ce7b70cb9e3d/kamada-%28kmda%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-13T18:57:34+00:00", "published_display": "13 May 2026 18:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/c1c58481-d8db-3a61-8361-1630ec6b40e2/kamada-ltd.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T16:48:15+00:00", "published_display": "13 May 2026 16:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates", "summary": "", "url": "https://finance.yahoo.com/news/kamada-kmda-q1-earnings-key-133004295.html", "source_name": "Zacks", "published_at": "2026-05-13T13:30:04+00:00", "published_display": "13 May 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Q1 2026 Earnings Call: Complete Transcript", "summary": "", "url": "https://finance.yahoo.com/news/kamada-q1-2026-earnings-call-125957107.html", "source_name": "Benzinga", "published_at": "2026-05-13T12:59:57+00:00", "published_display": "13 May 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/kamada-kmda-misses-q1-earnings-121502641.html", "source_name": "Zacks", "published_at": "2026-05-13T12:15:02+00:00", "published_display": "13 May 2026 12:15", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/kamada-q1-earnings-snapshot-111347538.html", "source_name": "Associated Press", "published_at": "2026-05-13T11:13:47+00:00", "published_display": "13 May 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Reports First Quarter 2026 Financial Results and", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxOaFdJTVRxZHZhTEdkVGN6VUV3MXY1bC1yS0ctZDh4TmdEOWtCQ0N2UkdYemp0bUJfanh3TVd4MlhHdkw3TnpuSnE4SFQtQ0JXQ1ZENnlxUHpVWFRVMlFEMXJ4SmJvYTQyN1BudkcwYnI2MjNzU0FQYVRFSDVYaHZBbFh1ckRBRkcxNS1WVnhfVUIwNmw3VTN1UnhGMXFWYXdIWEdhYkhnOUdGWnpVSVJrWEJJNDJLS21fZXh4a2hwcXEwdEJGY2xkaXIzQTdvLTIySXBGVVkxd1NJTlVhdEgxbjhMVWNkek9VRXA2aW5JRng2REY4Tl9qSE9RRTI0VWtaRjl5VkIxelpDdFp4cUhnWWJxREI1NDRCdWtmeXVqbzJlMF9waFo0TVVpdlhOeFdMUm1WM3pR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada shareholders face 25% tax holdback before April 7 dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeEZRS3RRbzVYSllMR0pENzFsTnRNVUhUcnpGR3JsRDlYM3JvV0w5VTlWSm9rUmtad1M3TlJXWXc4ODdVY3lmOVRtUUVMaVZFblRuOVE3NzVYUklvOGE5bnkxdmxCRy1UdGluZWEyX3VpdWl3dTJPX0FLLTlUNG9uSWp1S0hPeGliY0tYaUpsNjhuMW5YbGw5aXpIdDhKWm4wdkhQLWhldld1VzhLaDZZWW91dkxxYVpiWGZ3SElKT2Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade) (NASDAQ:KMDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxON1ZWQkJLTmtZalFtTWRfUDVvRk4yeVBkVzJKcjlqeWlXLXkxVGQyTERXNS1CNUNrb3R3VUNjSERxR1EzSjhJck9SdF9tYThzMVJMT3ZieHNkVV90bjM5T0I4VkhUMVdUSzdhS3M4Zk1QOU1GM1VGRWJXX2ZyYU44SzhBeFJfdURCa2dTSjVESWZSMW93a2NnbGs0NXhEWk1ZNVpkckxWb0FkQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Kamada's Texas site to sell plasma worth up to $10M a year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb0dleTVuNU01VUNtZUZZTXVJcEttTVhNdWhMMmYwRkJMZEhMZWljdGV5T2UtNjV3T0lZTE1WOXEtS0djcjVjRXpjOEhiZ2FJN0Uzb1NHYUV3RTJOeW12V3NsOU56UlJTZFk5MmVldmVjZTUxVGpMazRTdG5kclpJV1JLWG9DQVp4YkZEQXJKWVVtWnpEb3ppZEpOeGFXa18zWUlSTkFtZlV0NTRpbUFvLWRJcHcxdVZnRWV1VlJydUs?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada's Pipeline And Biosimilars Set Stage For Future Earnings Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQS0c1Q3hNSWFxaFAtZy1DdkMxQXQ3aGprVnVLSWRhbkRYeHRwcFRjQ2hna2JzV01rX1o1UHFJd0I3NlRFQUN5YWI1SGFTSTNqT0JKZ2VoMDhIaXJaWDdSVDNDSzQ4U3hMZzVvdlJVd1lmU1hUVGR6cmp4Njd6anRsaUZfU2p6R3h2RmJfb2tMY1NMVWJpLTllTU1DdGpZRXpKa25idzdOZVJfeGRFeWhVY0xrNA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (TASE:KMDA) Margin Expansion To 11.7% Challenges Cautious Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan aims to end 29-year losing streak against Mexico with Kamada-Kubo duo - CHOSUNBIZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFByMjFhX0QwUjJGc2VFNVRHZ2pWamlyNVFSMjBidWpQSzVJYmJrSUl6UmtJeExsY3ZlOUhXcmNkZ0plcWhoYzhwTFNoYTRBMUVOUWltRjV2ZEE3aTFsUU5acE9mTkd4VURfUXdkTV80WUlIMkdEeDdYdkRMLVV2cmfSAZMBQVVfeXFMTld0OEhZNmxrdEt3bE9YcHFfUzJIckJhVG1Fd0FtRU1XUlhVQ2xBa3N4Q3U4MVd6QlVjU0k1UF9UNGp0ejdrTTZxOWxPcVYwUldROGktOFdEbnRBYlY4enpUOGozbGpoZ1pueWd5eW1KWXFMOFV0SXB4WWc2NnIzaUxhM0VySV80YWFYT3BGV1czdmxJ?oc=5", "source_name": "Chosunbiz", "published_at": "2025-09-07T07:00:00+00:00", "published_display": "07 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FIFA World Cup 2026 Qualifiers: Crystal Palace\u2019s Kamada scores brace as Japan thrashes Indonesia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Sportstar", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada says Japan can close in on World Cup place against Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQRUk1ZkhocEY4UW5TTnJJTGJRSXBqTzU5Ykwzdk0xQjB4Q1hyVnhqcGpVVzM2QXhaNFBJQ053NHpLSTMwcVBVZmcxX3pGOFFxTEliNjJBZmFvNkc0T0dDc0M2empFVlROM2pkYUpZZlhvUWFEbmNTdkctYXR1QXBYZTgyYnJ3YXVlWVhjRUs2Y2IxN3IyRkVpeTFHdEltLUNpT2RLSVc2eXNJQnJXRWFJOGV4OUtMTlNHODB3cHJUUEdEc3pMYWhzdG5IV0NpWEt4V05LNDRn?oc=5", "source_name": "Flashscore.co.za", "published_at": "2024-10-11T07:00:00+00:00", "published_display": "11 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Football: Daichi Kamada, Takefusa Kubo headline Japan's World Cup squad", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBuOGc2M0lfLWJBcWlfUXVwMGpKcEZtQWpGbFVnRHJ6TlhjYW9fdWxTdmZWM1ZEVU83VGhNV25qR3RJS0NIZU9uYVZUcm5MeGNQOFJPSEo0XzdOZw?oc=5", "source_name": "Japan Wire by Kyodo News", "published_at": "2022-11-01T07:00:00+00:00", "published_display": "01 Nov 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada and Mitoma strike as Japan breeze past United States", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Times of India", "published_at": "2022-09-23T07:00:00+00:00", "published_display": "23 Sep 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kedrion and Kamada Announce FDA Approval of KEDRAB\u00ae Label Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNaEd1N0xnaWxwZGxRVWRYWEVsNlpncGhsbkN3a0hTak5DMFg2dWdPSUcyVmVvTE9hTVZiVDF5ZF93azJsLWFDYWx6V2pCSjBnQkxYWUJJdGdJb2xuSEk0WVZ2T3ZWbjU5SUFvUDh5d1EyeHRSaXB4Zzg0aEtFaUkzQlo4UW1tMDNHVHhJc21YbmIwdHFtZHFmZ19KTU1hQV9wRERnNHpHR0ZZQWRaVWloMDZxbXF6Q2VPWDZ6cTdWbE5FNGxJd2R0Qmc3c1NYSkhfOGZPZzJjMFo0LU93QzZGeGdKUzBqTUxRU2loWlJEclhpbGpH?oc=5", "source_name": "GuruFocus", "published_at": "2021-06-02T07:00:00+00:00", "published_display": "02 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye on Pharma: Alvotech and Kamada Team Up to Commercialize Biosimilars in Israel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSU14Z2toRkZHSGVIM3JvUGVsSW1UaWN6cUQ3UmZwcHlRbTdwWUxFYmxPc18xWWp1RGduT3lfSVNPclZCMnZiTk5XUzg1NzlZY3VaQVV1V2wtS3hWVHpVRWtKQWZLa0xoYkM1UkJURlRudUdpeGRwNHZxdzNsRUNBRlQ4SDB1aTVCcHlQVHo4SmRJNlB3Q05FWXhNdW1UcDB5cXVoZ0tHcm1jNzBlVERLbWpnamFTTi1RR195QW1YWQ?oc=5", "source_name": "Center for Biosimilars", "published_at": "2019-12-07T08:00:00+00:00", "published_display": "07 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Kamada (KMDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFAxSnpEeGtySGk3VENQaS1VMWxNZ0lqc2d6Mm1LbjZ3RUdENDI0d3NRVGlxUHhFVVcwSXhycm4yQlJQMFFab2c0eHdFRjNnZFdIWkF1clI5OG44RkxyRGVRc19JSWlsLVdIc3JwUA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-07-07T23:49:29+00:00", "published_display": "07 Jul 2016 23:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kamada highlights study results on CYTOGAM in transplants", "summary": "Kamada Ltd. presented positive study results for its CYTOGAM product at a recent International Society for Heart and Lung Transplant meeting, showing improved outcomes for high-risk lung transplant recipients. The company, which reported strong Q1 2026 revenues and reaffirmed its", "url": "https://www.investing.com/news/company-news/kamada-highlights-study-results-on-cytogam-in-transplants-93CH-4788076", "source_name": "Investing.com", "published_at": "2026-07-14T07:10:15", "published_display": "14 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNNnY3NUlJT09nNzZtekkzTXdjYkhrVWhMbjBtZGVWOUxDRmh0RmRrX0hpdVljUDBneVZ6aWtfV3pGNUtia0NhSzhpeWotYTRmeGh0cFBvMzJzaEdnNnBmS21fM1ZrODlzSHllVjBiSkFkZUh2SnJtTkZITVVjVXhWamhrVTB1NmhDY2JpSlFCb0k0ZEVGbGJydEY1TWtGd1g2V0I5OG1rb3JVYl9YYnpuSzB3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T12:17:22+00:00", "published_display": "13 Jul 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada highlights study results on CYTOGAM in transplants By Investing.com", "summary": "Kamada Ltd. announced positive results from an investigator-initiated study on its CYTOGAM product for solid organ transplantation, presented at the 2026 International Society for Heart and Lung Transplant annual meeting. The study indicated that high-risk lung transplant recipie", "url": "https://ng.investing.com/news/stock-market-news/kamada-highlights-study-results-on-cytogam-in-transplants-93CH-2596484", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:40:59", "published_display": "13 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC Filing - Form 6-K", "summary": "Kamada Ltd. (NASDAQ: KMDA) has filed a Form 6-K report highlighting new results from an Investigator-Initiated Study on its Cytomegalovirus Immune Globulin (CMVIG), CYTOGAM\u00ae, presented at the 2026 ISHLT annual meeting. The study indicates that CMVIG prophylaxis is associated with", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-ee81347ac99e.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:12:08", "published_display": "13 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Highlights CYTOGAM\u00ae Study Results Presented at the 2026 ISHLT Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kamada-highlights-cytogam-study-results-110000518.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immune drug CYTOGAM tied to better outcomes in high\u2011risk lung transplant patients", "summary": "Kamada (NASDAQ: KMDA) announced new data from an Investigator-Initiated Study demonstrating that its immune globulin product, CYTOGAM, is associated with improved outcomes in high-risk lung transplant recipients. Presented at the 2026 ISHLT annual meeting, the findings, which com", "url": "https://www.stocktitan.net/news/KMDA/kamada-highlights-cytogam-study-results-presented-at-the-2026-ishlt-re84r7b7tu3n.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:12:08", "published_display": "13 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (KMDA) Movements Inform Risk Allocation Models", "summary": "This article analyzes Kamada Ltd. (NASDAQ: KMDA) using AI models, identifying weak near-term sentiment but strong long-term potential. It provides three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The anal", "url": "https://news.stocktradersdaily.com/news_release/134/How_KMDA_Movements_Inform_Risk_Allocation_Models_071226044602_1783845962.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T06:45:52", "published_display": "12 Jul 2026 06:45", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kamada Ltd. \u2013 NASDAQ:KMDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPUUFXYjNmTjJFeDlMSm1wbnoxRzVyakk5TnlEem40RGVNUzFQR2RRUGYyMGN1VFM0eUJSTGs3V09hV3Bla0htWGJta3ZfamZIYVJOcll1dURBUWNCRW05S3NJLXA4Zjd0eGd6R0FmaFRNSndDdkVSX01sWU9UcEdWMlpvZnRUMVJWMmNmVmpiNGxhMjg3YkFMbHRuRVBkUDgyNEE?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T12:27:56+00:00", "published_display": "10 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd outlines plasma-derived therapies strategy. Investor focus on specialty biologics pipeline grows", "summary": "Kamada Ltd (KMDA) is a specialty biopharmaceutical company focused on plasma-derived and other biologic therapies for rare and serious conditions, listed on Nasdaq. The company's strategy involves controlling plasma fractionation, focusing on rare disease markets with in-house de", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-outlines-plasma-derived-therapies-strategy-investor-focus-on/69717196", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:30:00", "published_display": "07 Jul 2026 21:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines Slightly - Post-Earnings Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOeWM5S3ZIRnlycE1yVW5STnV0azdHVmdOWHREWFM5XzNxWDdaVTlLWWpuRGpGOHZCNU9tOV91UElBU3lLb1JyYU5TaVg5dVVPUUFxLXF1eTRtTzJFbG9MR1ZwTGJuRTY5ZGVQdTBubUxGcEdESUpIRFlwN2dYUWQ2NWJEWU9qU1V0dHBDVXdfbk1paEJMeFJjYkNaOXNJVDdTdWxnMmhSTV9sRUxjQXdUN1BpWjFxcGFs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-05T12:43:48+00:00", "published_display": "05 Jul 2026 12:43", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines Slightly - Trough Earnings Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPa256VkpYU3Q3Q1FCejJxMGFObWhpenlpLVpmaWh4VEx2TnVoZHhUWm5NSHYxdGVnblpZZTFPcWM2SHVhZWYxZkFxQ3NoeUVqQzl4a3A0SGc1UEhPZGQySkwydS1SWHlwbFlIS0xwZXBTNVY3TUJKVXByX1Z2SnNqUDdjaDVSd0tRSWg4TGpPNzAycF9VUWtmTlpaTVRHUzVGOXFFam5rUnFaTEhia0xjYWxDLVpLMXhSd0hrRA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd updates drug portfolio as Nasdaq-listed biopharma pursues growth", "summary": "Kamada Ltd, a Nasdaq-listed biopharma company, is refining its drug portfolio, focusing on specialty plasma-derived and hyperimmune globulin products for rare and underserved indications. The company, headquartered in Israel, offers US investors exposure to its niche through Amer", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-updates-drug-portfolio-as-nasdaq-listed-biopharma-pursues/69661013", "source_name": "AD HOC NEWS", "published_at": "2026-06-30T12:40:37", "published_display": "30 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Corporate Presentation Summary", "summary": "This article summarizes a corporate presentation by Kamada (KMDA) from December 12, 2025, highlighting its strong financial performance with 2025 revenue guidance of $178\u2013182M and significant year-over-year growth in revenue, gross profit, and adjusted EBITDA. The company boasts ", "url": "https://quartr.com/events/kamada-kmda-corporate-presentation_F9yDDt1k", "source_name": "Quartr", "published_at": "2026-06-27T17:39:51", "published_display": "27 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KMDA Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article analyzes Kamada Ltd's (KMDA) financial performance, highlighting its revenue breakdown, profitability margins, and competitive standing. Proprietary Products contribute the majority (85.9%) of its revenue. KMDA's margins, including a gross margin of 42.25% and a net m", "url": "https://intellectia.ai/en/stock/KMDA/financials", "source_name": "Intellectia AI", "published_at": "2026-06-23T23:41:20", "published_display": "23 Jun 2026 23:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Stock - weekly review against biotech peers", "summary": "This article provides a weekly review of Kamada stock (KMDA), noting its quiet trading in the mid-single digits without fresh company news. The focus is on how Kamada, an Israeli plasma-derived protein specialist, compares to its mid-cap biotech peers and its recent fundamentals.", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-stock-weekly-review-against-biotech-peers/69585732", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T20:18:33", "published_display": "19 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kamada Ltd (KMDA) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have an average price target of $13.00 for KMDA, with a \"Buy\" trend recommendation from three analysts. The company's expected revenue for the next quarter is $50.66M,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:11:00", "published_display": "18 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada schedules annual shareholder meeting for August in Rehovot", "summary": "Kamada Ltd. (NASDAQ:KMDA) has announced that its Annual General Meeting of Shareholders will be held on Wednesday, August 5, 2026, at 4:00 p.m. Israel time. The meeting will take place at the company's offices in Rehovot, Israel. A notice and proxy statement have been prepared an", "url": "https://www.investing.com/news/sec-filings/kamada-schedules-annual-shareholder-meeting-for-august-in-rehovot-93CH-4749556", "source_name": "Investing.com", "published_at": "2026-06-18T11:39:32", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (NASDAQ: KMDA) plans 2026 AGM on directors, option grants and ISO pool", "summary": "Kamada Ltd. will hold its Annual General Meeting of Shareholders on August 5, 2026, to vote on the re-election of directors, approve equity option grants for nominees, and amend the U.S. Taxpayers Appendix of its 2011 Israeli Share Award Plan to increase the incentive stock optio", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-ea617ad2d2c4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T10:39:32", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Kamada Ltd (KMDA), noting its current valuation score of 8.07, which ranks it 113 out of 157 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 20.72, showing a significant deviation from its recent high and low", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:32", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kamada Ltd (KMDA), detailing its current price momentum score of 6.81, ranking 96 out of 157 in the Pharmaceuticals industry. It highlights the stock trading between resistance at $7.84 and support at $6.88, suggesting suitability for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:32", "published_display": "18 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Kamada Ltd (KMDA), detailing its current risk score of 4.17 and ranking it 91 out of 157 in the Pharmaceuticals industry. Key metrics like beta (0.87), maximum drawdown, volatility, and Sharpe ratios are presented to illustrate the stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T07:11:10", "published_display": "18 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kamada Ltd (KMDA), detailing its revenue by region. The data shows the United States accounts for the majority of revenue at 55.22%, followed by Israel, Latin America, Canada, and Europe. The report also notes that specific data for b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kmda/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:11:10", "published_display": "18 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after rece", "summary": "Kamada Ltd, an Israeli biopharmaceutical company, specializing in plasma-derived products and inhaled therapies, has experienced recent stock weakness despite its strategic focus. The company develops and markets treatments for rare and serious conditions, including alpha-1 antit", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-stock-il0010952647-biopharma-player-focuses-on-plasma-and/69515074", "source_name": "AD HOC NEWS", "published_at": "2026-06-11T05:40:48", "published_display": "11 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after recent share weakness", "summary": "Kamada Ltd, an Israeli biopharma company, continues to focus on specialty plasma-derived products and inhaled therapies despite recent stock weakness. The company develops, manufactures, and markets products for rare and serious conditions, including AAT deficiency and immune def", "url": "https://www.ad-hoc-news.de/news/ueberblick/kamada-ltd-stock-il0010952647-biopharma-player-focuses-on-plasma-and/69515074", "source_name": "AD HOC NEWS", "published_at": "2026-06-10T15:10:40", "published_display": "10 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory", "summary": "Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, will enhance Kamada's capabilities for Anti-Rabies potency testin", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kamada-announces-fda-approval-house-110000158.html", "source_name": "Market source", "published_at": "2026-06-03T20:10:39", "published_display": "03 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada receives FDA approval for rabies antibody testing lab", "summary": "Kamada Ltd. announced that the U.S. FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel for potency testing of its anti-rabies products, KEDRAB and KAMRAB. This approval follows prior authorizations from Health Canada and the Isr", "url": "https://www.investing.com/news/company-news/kamada-receives-fda-approval-for-rabies-antibody-testing-lab-93CH-4718870", "source_name": "Investing.com", "published_at": "2026-06-02T02:39:01", "published_display": "02 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada receives FDA approval for rabies antibody testing lab By Investing.com", "summary": "Kamada Ltd. announced FDA approval for its new Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel. This lab will conduct potency testing for their anti-rabies products, KEDRAB and KAMRAB, which generated over $70 million in sales in 2025. The approval is expecte", "url": "https://ca.investing.com/news/stock-market-news/kamada-receives-fda-approval-for-rabies-antibody-testing-lab-93CH-4668431", "source_name": "Investing.com Canada", "published_at": "2026-06-01T11:40:20", "published_display": "01 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rabies antibody testing: FDA approves Kamada\u2019s rare gold-standard lab", "summary": "Kamada (NASDAQ: KMDA) has received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory located in Beit Kama, Israel. This lab significantly expands the company's testing capabilities for its anti-rabies products", "url": "https://www.stocktitan.net/news/KMDA/kamada-announces-fda-approval-of-its-new-in-house-rabies-virus-k1oab5qc525f.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:40:20", "published_display": "01 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) wins FDA approval for in-house RFFIT rabies antibody testing lab", "summary": "Kamada Ltd. (NASDAQ: KMDA) announced that the FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This lab, located in Israel and previously approved by Health Canada and the Israeli Ministry of Health, will be used for Anti-Rabies potenc", "url": "https://www.stocktitan.net/sec-filings/KMDA/6-k-kamada-ltd-current-report-foreign-issuer-a7d7be1d4fdb.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:40:20", "published_display": "01 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KMDA - Kamada Ltd Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Kamada Ltd (KMDA), a biopharmaceutical company specializing in plasma-derived therapeutics. It includes real-time stock quotes, key financial metrics, insider ownership, analyst ratings, and a chronological list of r", "url": "https://finviz.com/stock?t=KMDA", "source_name": "Finviz", "published_at": "2026-06-01T02:08:54", "published_display": "01 Jun 2026 02:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Holds Steady Near Support as Trading Volume Remains Moderate - Shakeout Pattern", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPVTFveUJILVExTmdVTDNjQmd0UzRQNnV3SXM4MGd6Zk8xcGttMXRKTVdyV2Q0QnFRRGg0aVRiRXdrSGJCZGcxOG03MHFJTEUxbTVER1FmYW80R1BSQU9jSGxnYy0xOGo4TGFqSmdnWENDcDhobFFVQm03YURIN0pKaXZPeTR6V1JpY2tpd2hvbHd6a3FtOC1OdkFEaS1CNFVPYXY5UDFlN09LUk9FTTlBODZzYmo3VVU0WVVz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Edges Lower: Key Levels to Watch Amid Sector Dynamics - Bull Flag", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQ2x5YzVLS1JVT2MtQzFmQ0YzLTR4OW5yNW8tUVBnbjFaal9MdjRSbHJmT0ZFQzhNSlRpdWJySm53bzhHSWVPelFFQ3JObWNBN2c0allTa3ZQRk12MHlBOWcybHZEdUp6UUFYRjk2Zlp2a0VxTndMY2JpNUdjeEFpemVwSENwZUc4MEppVFRTXzBQcmtEVjk3bHB4cmFpQUlsTXZ5QzVaTzh1dmdOMmpMa0YyR0xZSHlT?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. (KMDA) Edges Lower: Key Levels to Watch Amid Sector Dynamics - Volume Rate Change", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMjhSWXVuckpYenZuT0FOMzdzS1VUUHRvNi1jbjZiWms2RUthWElsQVlwNFF6cXdNekFWU0dBY3ltYWV6aVVPU09wLU1iU0FYMW9PZEg1d3pfdVVXTkhHd2tiRkg4S0k0NUh0WUZRRXNoNExwRmhPOUpjZWw0SEV2aWlxZUNIQ2FLQ1JDUjM5RzZtaTZXRmRMWUJPOU4xNzhDeG5aRmJwWko2SldwVzJDWXFYSVBWQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me", "summary": "Kamada Ltd (KMDA) shares are stabilizing on Nasdaq following its latest quarterly update, which provided fresh insight into its revenue and margin trends for 2025. Investors are now reassessing the Israeli biopharmaceutical group's earnings profile and valuation multiples, contri", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kamada-ltd-stock-il0010952647-shares-stabilize-after-recent-results-as/69439344", "source_name": "Ad Hoc News", "published_at": "2026-05-29T06:39:23", "published_display": "29 May 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Q1 Earnings Call Highlights", "summary": "Kamada reiterated its full-year 2026 outlook, with management stating that Q1 results were in line with expectations despite a temporary shipment delay. The company projects revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million for 2026, driven", "url": "https://www.tradingview.com/news/marketbeat:3f5df9636094b:0-kamada-q1-earnings-call-highlights/", "source_name": "TradingView", "published_at": "2026-05-28T00:40:04", "published_display": "28 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kamada-ltd-kmda-q1-2026-230135936.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:01:35+00:00", "published_display": "13 May 2026 23:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/3e7bb77a-ff9d-3541-9e49-ce7b70cb9e3d/kamada-%28kmda%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-13T18:57:34+00:00", "published_display": "13 May 2026 18:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/c1c58481-d8db-3a61-8361-1630ec6b40e2/kamada-ltd.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T16:48:15+00:00", "published_display": "13 May 2026 16:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates", "summary": "", "url": "https://finance.yahoo.com/news/kamada-kmda-q1-earnings-key-133004295.html", "source_name": "Zacks", "published_at": "2026-05-13T13:30:04+00:00", "published_display": "13 May 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Q1 2026 Earnings Call: Complete Transcript", "summary": "", "url": "https://finance.yahoo.com/news/kamada-q1-2026-earnings-call-125957107.html", "source_name": "Benzinga", "published_at": "2026-05-13T12:59:57+00:00", "published_display": "13 May 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/news/kamada-kmda-misses-q1-earnings-121502641.html", "source_name": "Zacks", "published_at": "2026-05-13T12:15:02+00:00", "published_display": "13 May 2026 12:15", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/kamada-q1-earnings-snapshot-111347538.html", "source_name": "Associated Press", "published_at": "2026-05-13T11:13:47+00:00", "published_display": "13 May 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada Reports First Quarter 2026 Financial Results and", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxOaFdJTVRxZHZhTEdkVGN6VUV3MXY1bC1yS0ctZDh4TmdEOWtCQ0N2UkdYemp0bUJfanh3TVd4MlhHdkw3TnpuSnE4SFQtQ0JXQ1ZENnlxUHpVWFRVMlFEMXJ4SmJvYTQyN1BudkcwYnI2MjNzU0FQYVRFSDVYaHZBbFh1ckRBRkcxNS1WVnhfVUIwNmw3VTN1UnhGMXFWYXdIWEdhYkhnOUdGWnpVSVJrWEJJNDJLS21fZXh4a2hwcXEwdEJGY2xkaXIzQTdvLTIySXBGVVkxd1NJTlVhdEgxbjhMVWNkek9VRXA2aW5JRng2REY4Tl9qSE9RRTI0VWtaRjl5VkIxelpDdFp4cUhnWWJxREI1NDRCdWtmeXVqbzJlMF9waFo0TVVpdlhOeFdMUm1WM3pR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada shareholders face 25% tax holdback before April 7 dividend", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeEZRS3RRbzVYSllMR0pENzFsTnRNVUhUcnpGR3JsRDlYM3JvV0w5VTlWSm9rUmtad1M3TlJXWXc4ODdVY3lmOVRtUUVMaVZFblRuOVE3NzVYUklvOGE5bnkxdmxCRy1UdGluZWEyX3VpdWl3dTJPX0FLLTlUNG9uSWp1S0hPeGliY0tYaUpsNjhuMW5YbGw5aXpIdDhKWm4wdkhQLWhldld1VzhLaDZZWW91dkxxYVpiWGZ3SElKT2Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade) (NASDAQ:KMDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxON1ZWQkJLTmtZalFtTWRfUDVvRk4yeVBkVzJKcjlqeWlXLXkxVGQyTERXNS1CNUNrb3R3VUNjSERxR1EzSjhJck9SdF9tYThzMVJMT3ZieHNkVV90bjM5T0I4VkhUMVdUSzdhS3M4Zk1QOU1GM1VGRWJXX2ZyYU44SzhBeFJfdURCa2dTSjVESWZSMW93a2NnbGs0NXhEWk1ZNVpkckxWb0FkQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Kamada's Texas site to sell plasma worth up to $10M a year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb0dleTVuNU01VUNtZUZZTXVJcEttTVhNdWhMMmYwRkJMZEhMZWljdGV5T2UtNjV3T0lZTE1WOXEtS0djcjVjRXpjOEhiZ2FJN0Uzb1NHYUV3RTJOeW12V3NsOU56UlJTZFk5MmVldmVjZTUxVGpMazRTdG5kclpJV1JLWG9DQVp4YkZEQXJKWVVtWnpEb3ppZEpOeGFXa18zWUlSTkFtZlV0NTRpbUFvLWRJcHcxdVZnRWV1VlJydUs?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada's Pipeline And Biosimilars Set Stage For Future Earnings Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQS0c1Q3hNSWFxaFAtZy1DdkMxQXQ3aGprVnVLSWRhbkRYeHRwcFRjQ2hna2JzV01rX1o1UHFJd0I3NlRFQUN5YWI1SGFTSTNqT0JKZ2VoMDhIaXJaWDdSVDNDSzQ4U3hMZzVvdlJVd1lmU1hUVGR6cmp4Njd6anRsaUZfU2p6R3h2RmJfb2tMY1NMVWJpLTllTU1DdGpZRXpKa25idzdOZVJfeGRFeWhVY0xrNA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada (TASE:KMDA) Margin Expansion To 11.7% Challenges Cautious Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan aims to end 29-year losing streak against Mexico with Kamada-Kubo duo - CHOSUNBIZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFByMjFhX0QwUjJGc2VFNVRHZ2pWamlyNVFSMjBidWpQSzVJYmJrSUl6UmtJeExsY3ZlOUhXcmNkZ0plcWhoYzhwTFNoYTRBMUVOUWltRjV2ZEE3aTFsUU5acE9mTkd4VURfUXdkTV80WUlIMkdEeDdYdkRMLVV2cmfSAZMBQVVfeXFMTld0OEhZNmxrdEt3bE9YcHFfUzJIckJhVG1Fd0FtRU1XUlhVQ2xBa3N4Q3U4MVd6QlVjU0k1UF9UNGp0ejdrTTZxOWxPcVYwUldROGktOFdEbnRBYlY4enpUOGozbGpoZ1pueWd5eW1KWXFMOFV0SXB4WWc2NnIzaUxhM0VySV80YWFYT3BGV1czdmxJ?oc=5", "source_name": "Chosunbiz", "published_at": "2025-09-07T07:00:00+00:00", "published_display": "07 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FIFA World Cup 2026 Qualifiers: Crystal Palace\u2019s Kamada scores brace as Japan thrashes Indonesia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Sportstar", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada says Japan can close in on World Cup place against Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQRUk1ZkhocEY4UW5TTnJJTGJRSXBqTzU5Ykwzdk0xQjB4Q1hyVnhqcGpVVzM2QXhaNFBJQ053NHpLSTMwcVBVZmcxX3pGOFFxTEliNjJBZmFvNkc0T0dDc0M2empFVlROM2pkYUpZZlhvUWFEbmNTdkctYXR1QXBYZTgyYnJ3YXVlWVhjRUs2Y2IxN3IyRkVpeTFHdEltLUNpT2RLSVc2eXNJQnJXRWFJOGV4OUtMTlNHODB3cHJUUEdEc3pMYWhzdG5IV0NpWEt4V05LNDRn?oc=5", "source_name": "Flashscore.co.za", "published_at": "2024-10-11T07:00:00+00:00", "published_display": "11 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Football: Daichi Kamada, Takefusa Kubo headline Japan's World Cup squad", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBuOGc2M0lfLWJBcWlfUXVwMGpKcEZtQWpGbFVnRHJ6TlhjYW9fdWxTdmZWM1ZEVU83VGhNV25qR3RJS0NIZU9uYVZUcm5MeGNQOFJPSEo0XzdOZw?oc=5", "source_name": "Japan Wire by Kyodo News", "published_at": "2022-11-01T07:00:00+00:00", "published_display": "01 Nov 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kamada and Mitoma strike as Japan breeze past United States", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Times of India", "published_at": "2022-09-23T07:00:00+00:00", "published_display": "23 Sep 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kedrion and Kamada Announce FDA Approval of KEDRAB\u00ae Label Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNaEd1N0xnaWxwZGxRVWRYWEVsNlpncGhsbkN3a0hTak5DMFg2dWdPSUcyVmVvTE9hTVZiVDF5ZF93azJsLWFDYWx6V2pCSjBnQkxYWUJJdGdJb2xuSEk0WVZ2T3ZWbjU5SUFvUDh5d1EyeHRSaXB4Zzg0aEtFaUkzQlo4UW1tMDNHVHhJc21YbmIwdHFtZHFmZ19KTU1hQV9wRERnNHpHR0ZZQWRaVWloMDZxbXF6Q2VPWDZ6cTdWbE5FNGxJd2R0Qmc3c1NYSkhfOGZPZzJjMFo0LU93QzZGeGdKUzBqTUxRU2loWlJEclhpbGpH?oc=5", "source_name": "GuruFocus", "published_at": "2021-06-02T07:00:00+00:00", "published_display": "02 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye on Pharma: Alvotech and Kamada Team Up to Commercialize Biosimilars in Israel", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNSU14Z2toRkZHSGVIM3JvUGVsSW1UaWN6cUQ3UmZwcHlRbTdwWUxFYmxPc18xWWp1RGduT3lfSVNPclZCMnZiTk5XUzg1NzlZY3VaQVV1V2wtS3hWVHpVRWtKQWZLa0xoYkM1UkJURlRudUdpeGRwNHZxdzNsRUNBRlQ4SDB1aTVCcHlQVHo4SmRJNlB3Q05FWXhNdW1UcDB5cXVoZ0tHcm1jNzBlVERLbWpnamFTTi1RR195QW1YWQ?oc=5", "source_name": "Center for Biosimilars", "published_at": "2019-12-07T08:00:00+00:00", "published_display": "07 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Kamada (KMDA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFAxSnpEeGtySGk3VENQaS1VMWxNZ0lqc2d6Mm1LbjZ3RUdENDI0d3NRVGlxUHhFVVcwSXhycm4yQlJQMFFab2c0eHdFRjNnZFdIWkF1clI5OG44RkxyRGVRc19JSWlsLVdIc3JwUA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-07-07T23:49:29+00:00", "published_display": "07 Jul 2016 23:49", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 91, "total_relevant": 56, "sentiment_summary": {"positive": 21, "negative": 8, "neutral": 27, "score": 56, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.6, "count": 24}, {"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 7.12, "latest_week": "2026-07-10", "one_week_move": -5.1, "four_week_move": -4.3, "twelve_week_move": -16.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.349914, "market_dynamics_buy_signal": false, "relative_strength": -17.865325, "fair_value_gap": 14.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.8583, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.1% over one week, -4.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "AD HOC NEWS", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "Donan\u0131mHaber", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 23}, {"label": "Regulatory and legal", "count": 6}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.1% over one week, -4.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Kamada highlights study results on CYTOGAM in transplants"}], "updated_at": "2026-07-16T11:50:17.720048+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}